Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Editas gets new CRISPR IP from academia

Executive Summary

Editas Medicine Inc. received exclusive worldwide rights to new CRISPR IP from the Broad Institute, Harvard University, Massachusetts Institute of Technology, Wageningen University, the University of Iowa, and the University of Tokyo. The deal operates under Broad/Harvard/MIT's inclusive innovation model, which, under certain circumstances, allows the research institutions to license IP outside of Editas' scope to third parties.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies